A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus

CONCLUSION: Plasma exposure of SY-009 and its metabolites was fairly low in T2DM patients at doses of 1.0-4.0 mg. SY-009 reduced postprandial glucose, C-peptide, and insulin levels, showing relative safety and tolerability in the dose range of 1.0-4.0 mg.TRIALS REGISTRATION: ClinicalTrials.gov Identifier: NCT04345107.PMID:37981049 | DOI:10.1016/j.ejps.2023.106644

Source: European Journal of Pharmaceutical Sciences - November 19, 2023 Category: Drugs & Pharmacology Authors: Lei Huang Bei Cao Yan Geng Xiaoli Zhou Yuanxun Yang Tingting Ma Hui Lin Zhijiang Huang Lang Zhuo Juan Li Source Type: research